OncoDNA anticipates a strong increase in the use of OncoDNA profiling products in Europe with the partnerships with Gammaray and AMS.
The deal covers Cancer Genetics' microarray-based Tissue of Origin test, which analyzes 2,000 individual tumor genes to help identify a tumor's origin.
The three-year extension increases the minimum purchase commitments for the Unyvero system, resulting in an increase in potential revenues of €30 million to Curetis.
Immunoscore Colon predicts the risk of recurrence in patients with early-stage colon cancer and guides oncologists in decisions about therapies for stage II and III colon cancers.
The tests are based on a technology that uses Fourier transform infrared spectroscopy and a proprietary technique that analyzes spectrometer test results.
TSG is a wholly owned subsidiary of Ascendis Medical and supplies diagnostic laboratory equipment and consumables to pathology laboratories.
Lucence's test are designed to detect DNA fragments shed by a tumor into the blood and target the most common cancers in Asia such as lung cancer.
The battery-operated, hand-held device uses a broad-spectrum photometric method to provide accurate hemoglobin measurements in about one second.
The deal cover's Sienna's in vitro diagnostic for the detection of the hTERT component of telomerase, a biomarker that aids in the diagnosis of bladder cancer.
As part of the agreements, the distributors have committed to purchase a minimum number of Curetis' molecular diagnostic systems over three years.